Apollomics IncAPLM
Price$24.95

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2024
Net Income -$53.9MTTM through 31 Dec 2024
Free Cash Flow -$28.8MTTM through 31 Dec 2024

Margins

Current

Returns

343.2%ROE
-162.9%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio0.96x
Net Debt-$3.3Mnet cash position
Cash & Equivalents$9.8M

Quality Metrics

Piotroski F-Score2 / 9

Multi-Year Trend

Revenue
'20'21'22'23'24
FY2024: $0
Diluted EPS
'20'21'22'23'24
FY2024: $-52.80

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Oncology Drug Development$8.5M
View details

The company is prioritizing vebreltinib development for NSCLC with MET amplification and plans to submit a U.S. IND for accelerated approval in the first half of 2027.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.